Skip to content
Nobel Jews

Nobel Prize in Physiology or Medicine · 2002

H. Robert Horvitz

Found the genes that tell cells when to die, a worm discovery that changed how we understand cancer and brain disease.

The Nobel citation: “for their discoveries concerning genetic regulation of organ development and programmed cell death”
Born
May 8, 1947, Chicago, IL, USA
Shared with
Sydney Brenner, John E. Sulston
Affiliation at the time
Massachusetts Institute of Technology (MIT), USA

Medicine prize

2002

Shared with 2 other laureates.

Age that year

55years

Born in 1947.

Sources cited

17

Fact-checked September 24, 2026.

  • Of the 1,090 cells made as a C. elegans worm develops, exactly 131 die on schedule. Horvitz found the genes that carry out those deaths.
  • He came to biology late: he earned MIT degrees in mathematics and economics and took his first biology course as a senior.
  • His first name, Howard, starts with H in memory of his great-grandfather Hersch, who was murdered by the Nazis.
  • After his father fell ill with ALS, Horvitz joined the team that in 1993 found the first gene known to cause inherited ALS.
  • Sydney Brenner was his fourth research supervisor to win a Nobel Prize, after Robert Solow, James Watson and Walter Gilbert.

The breakthrough

Discovering the genes that control programmed cell death

Your body is built by adding cells, but also by removing them. Before birth, for example, the cells between your fingers die so the fingers can separate. Biologists called this orderly cell suicide programmed cell death, but nobody knew whether genes controlled it. Horvitz studied a see-through worm about 1 millimetre long, Caenorhabditis elegans, whose every cell can be watched under a microscope. As the worm develops, 1,090 cells form and exactly 131 of them die, in the same places every time. In 1986 Horvitz and his student Hilary Ellis showed that two genes, ced-3 and ced-4, are needed for those deaths. If either gene is broken, the doomed cells survive. His lab then found ced-9, a gene that protects cells that should live, and egl-1, which switches that protection off in cells meant to die. Think of it as a self-destruct button with a safety catch, plus a hand that can release the catch. The big surprise came in 1992, in findings published in 1993 and 1994. CED-9 turned out to resemble human BCL-2, a gene that helps some cancers survive. CED-3 resembled a human enzyme, and the two became the founding members of the caspases, the enzymes that take a dying cell apart. At its core, the worm's machinery for cell death was also ours.[2],[3],[4],[5],[6],[7],[9]

“Time and time again, truly basic studies of simple experimental organisms have proved directly relevant to human biology and human disease.”
H. Robert Horvitz, From his Nobel Lecture, "Worms, Life and Death," given in Stockholm on December 8, 2002, arguing for public funding of basic research.[3]

What it meant for humanity

Horvitz did not set out to cure anything. In his Nobel lecture he said his research targeted no disease. But his worm genes gave medicine a map of how cells decide to die. Too little cell death lets damaged cells pile up, as in some cancers and autoimmune disorders. Too much kills cells we need, as in stroke, heart attack and brain diseases such as Alzheimer's and ALS. Once his lab showed that the worm's death genes match human ones, researchers could study human cell death piece by piece. On the day in 1993 that the CED-3 findings were published, scientists from five drug companies called him to ask how to use them. The clearest payoff so far is in blood cancers. The worm's egl-1 protein switches off the ced-9 safety catch. Venetoclax, a drug approved in the United States in 2016, does the same to human BCL-2: it mimics the natural release signal and lets leukemia cells die. It is now used for chronic lymphocytic leukemia and acute myeloid leukemia. Credit for the drug belongs to many laboratories that worked on the BCL-2 family in mammals. Horvitz's work helped show that this family runs a core, ancient death program. His second contribution grew out of grief. After his father developed ALS, Horvitz helped find the first gene known to cause inherited ALS, SOD1. In 2023 US regulators approved tofersen, a drug that lowers production of the SOD1 protein. He also trained scientists who went on to discover microRNAs, a whole new class of gene regulators.

  • In 1986 Horvitz and Hilary Ellis identified ced-3 and ced-4, the first true 'death genes': without them, cells that should die survive instead.[2],[5]
  • His lab showed in 1993-94 that the worm genes ced-3 and ced-9 match human genes: an enzyme family now called caspases, and the cancer gene BCL-2.[3],[6],[7]
  • Venetoclax, which blocks BCL-2 by mimicking natural 'release' proteins like the worm's EGL-1, was approved in 2016 for chronic lymphocytic leukemia and in 2018 for acute myeloid leukemia.[3],[12],[13]
  • He was a principal member of the team that in 1993 linked the SOD1 gene to inherited ALS; in 2023 the FDA approved tofersen, a drug that targets SOD1.[8],[9],[11],[14]
  • Victor Ambros and Gary Ruvkun began their studies of developmental timing as postdocs in his lab. Their later work revealed microRNAs and earned them the 2024 Nobel Prize in Physiology or Medicine.[3],[17]

Impact in numbers

Horvitz turned programmed cell death from a description into a genetic pathway: a killer (ced-3), its helper (ced-4), a protector (ced-9) and a switch that disables the protector (egl-1). Because each piece has a human counterpart (caspases, APAF-1, BCL-2 and the BH3-only proteins), this worm pathway became a framework for studying cell death in cancer, neurodegeneration, stroke and autoimmunity. Its most concrete medical descendant is venetoclax, a BCL-2 blocker now used against leukemia. But that drug grew mainly from decades of mammalian BCL-2 research by many teams, so we do not assign Horvitz a numerical share of its benefit. We also found no reliable published count of patients treated. His ALS work helped identify SOD1, the target of the 2023 drug tofersen, which serves a small patient group and whose clinical benefit was still being confirmed at approval. His lasting impact is best measured in understanding: the principle that simple animals can reveal human biology, and the scientists he trained.

HealthFundamental science

No number is given here on purpose. Some contributions cannot be counted honestly, and we would rather describe them than invent a figure.

The double edge

No harms have been traced to Horvitz's own research, and we found no controversies about his conduct. The drugs that grew from cell-death biology do carry risks. Venetoclax kills cancer cells so fast that their contents can flood the blood, a condition called tumor lysis syndrome, which caused a few deaths in trials. It can also cause severely low white blood cell counts. Some cancers become resistant to it through new mutations. Tofersen was approved on the basis of a blood marker of nerve damage. In its main trial it lowered that marker but did not improve patients' function on the trial's main measure, and a confirmatory trial was still running when it was approved.

  • Moderate

    Serious side effects of the BCL-2 drug venetoclax

    Venetoclax can trigger tumor lysis syndrome, which was linked to deaths in a few trial patients, and severe neutropenia (very low white blood cell counts). Cancers can also escape it through mutations in BCL-2. These risks belong to the drug and its developers, not to Horvitz's worm research, but they are part of the story of cell-death medicine.[12],[13]

  • Minor

    An ALS drug approved on a surrogate marker

    The US approval of tofersen for SOD1-linked ALS was an accelerated approval based on lower levels of a blood marker of nerve damage. In its phase 3 trial the drug did not significantly improve the main measure of patients' function over 28 weeks, and serious neurological side effects occurred in 7% of those treated. Its clinical benefit was still being tested at the time of approval.[14],[16]

Against the odds

Horvitz's own path was not blocked by antisemitism, and it is fair to say so. He grew up in postwar Chicago in a mostly Jewish neighborhood, and in 1964 he went to MIT. By then the quotas that had limited Jewish students at many American universities since the 1920s were fading, though some lasted into the early 1960s. His family's history was much harsher. His paternal grandfather's father ran a lumber business in the Russian Empire but, as a Jew, was not allowed to own land. His paternal grandmother was arrested by the Tsar's police in 1905, warned she would be killed if caught again, and left for Chicago. On his mother's side, his great-grandfather and at least three of his grandmother's siblings were murdered by the Nazis. Horvitz carries that memory in his name. His father grew up poor; during the Depression his father's family sometimes lived on leftover dairy from his milk-delivery job. Horvitz also had severe asthma from the age of two and a half. He wrote that it made him more determined, not more afraid.

  • —

    Family killed

    His great-grandfather Hersch David Bleiweiss and at least three of his maternal grandmother's siblings were murdered by the Nazis. Horvitz's first name, Howard, was chosen in Hersch's memory.[1]

  • 1905

    Persecution

    In the Russian Empire, his great-grandfather could not own land because he was Jewish. His grandmother Celia was arrested by the Tsar's police during the 1905 uprising and later left Russia for Chicago.[1]

  • —

    Poverty

    During the Depression his father's family, deserted by its breadwinner, moved often for free rent and sometimes lived on leftover dairy from his father's job as a milkman's helper.[1]

  • 1949

    Other

    He developed severe asthma at age two and a half. For years it kept him out of most sports and sometimes left him bedridden or hospitalized, including during travels in Europe as a graduate student.[1]

  • —

    Discrimination

    Wider context: from the 1920s into the early 1960s, universities such as Harvard and Yale limited the number of Jewish students they admitted. By the time Horvitz entered MIT in 1964 these quotas were fading, and he describes no such barrier in his own life.[1],[15]

Jewish background

Both parents JewishCulturally Jewish

Horvitz was born in Chicago to Mary Savit Horvitz and Oscar Horvitz. In his Nobel autobiography he writes that both parents were children of Jewish immigrants from Eastern Europe: his grandparents came from what are now Ukraine, Belarus and Poland. He grew up in a mostly Jewish Chicago neighborhood but describes his family home as quite secular. Jewish memory still shaped the family. He was named for a great-grandfather murdered by the Nazis. He chose his daughter's name partly to honor his late father's Hebrew name, Asher. His mother supported the National Council of Jewish Women.[1]

Key dates

  1. May 8, 1947

    Born Howard Robert Horvitz in Chicago, Illinois, to the children of Jewish immigrants from Eastern Europe.[1],[4]

  2. 1964

    Enters MIT, where he earns degrees in mathematics and economics and takes his first biology course as a senior.[1]

  3. September 1968

    Begins graduate study in biology at Harvard, later working with James Watson and Walter Gilbert.[1]

  4. November 1974

    After a Harvard PhD, joins Sydney Brenner's lab in Cambridge, England, and teams up with John Sulston to trace the worm's cell lineage.[1],[3],[9]

  5. 1977

    Publishes with Sulston the complete post-embryonic cell lineages of C. elegans.[3],[10]

  6. January 1978

    Opens his own laboratory as a faculty member in MIT's Department of Biology.[1],[9]

  7. March 1986

    With Hilary Ellis, reports that genes ced-3 and ced-4 are required for programmed cell death.[2],[5]

  8. 1989

    His father, Oscar Horvitz, dies of ALS, deepening Horvitz's commitment to research on the disease.[1]

  9. March 1993

    Is part of the team that links mutations in the SOD1 gene to inherited ALS.[8],[9]

  10. November 1993

    His lab shows that the worm death gene ced-3 resembles a human enzyme, founding the caspase family.[3],[6]

  11. February 1994

    Shows that the worm survival gene ced-9 is a functional counterpart of the human cancer gene BCL-2.[7]

  12. October 7, 2002

    Awarded the Nobel Prize in Physiology or Medicine with Sydney Brenner and John Sulston.[2],[4]

  13. April 2016

    Venetoclax, a drug that blocks BCL-2, is approved in the US for a form of chronic lymphocytic leukemia.[12],[13]

Sources

  1. 1.H. Robert Horvitz – Biographical · NobelPrize.org (Nobel Prize Outreach), 2002
  2. 2.Press release: The Nobel Prize in Physiology or Medicine 2002 · The Nobel Assembly at Karolinska Institutet, 2002
  3. 3.Worms, Life and Death (Nobel Lecture, December 8, 2002) · NobelPrize.org (Nobel Prize Outreach), 2002
  4. 4.H. Robert Horvitz – Facts · NobelPrize.org (Nobel Prize Outreach)
  5. 5.Genetic control of programmed cell death in the nematode C. elegans (Ellis & Horvitz, Cell 44:817-829) · Cell / PubMed, 1986
  6. 6.The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme (Yuan et al., Cell 75:641-652) · Cell / PubMed, 1993
  7. 7.C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2 (Hengartner & Horvitz, Cell 76:665-676) · Cell / PubMed, 1994
  8. 8.Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis (Rosen et al., Nature 362:59-62) · Nature / PubMed, 1993
  9. 9.H. Robert Horvitz – Investigator profile · McGovern Institute for Brain Research at MIT
  10. 10.H. Robert Horvitz – Faculty profile · MIT Department of Biology
  11. 11.H. Robert Horvitz – Scientist profile · Howard Hughes Medical Institute
  12. 12.Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer (Lee & Fairlie, Biochem Soc Trans) · Biochemical Society Transactions / PMC, 2021
  13. 13.Venetoclax · Wikipedia
  14. 14.FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene · U.S. Food and Drug Administration, 2023
  15. 15.Jewish quota · Wikipedia
  16. 16.Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (Miller et al., N Engl J Med 387:1099-1110) · New England Journal of Medicine / PubMed, 2022
  17. 17.Press release: The Nobel Prize in Physiology or Medicine 2024 · The Nobel Assembly at Karolinska Institutet, 2024

Fact-checked on September 24, 2026 by a separate AI fact-checking pass that re-opened the sources, with 7 corrections made. How we check

Suggest a correction